A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder
ConditionMajor Depressive Disorder
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-65
SponsorBristol-Myers Squibb
About this trial
A Study to Evaluate BMS-986511 in Adults with Major Depressive Disorder
Eligibility criteria
Qualifiers
Participants must meet the MDD diagnosis per DSM-5 criteria confirmed by structured interview.
Participant must have current moderate to severe MDE confirmed by clinical assessment and validated scale.
Participant must have current MDE duration >12 weeks at screening.
Outpatient participants able to comply with study procedures.
Disqualifiers
Participants must not have other primary psychiatric disorders or a history of treatment-resistant depression during the current episode.
Participants must not have recent history of active suicidal ideation or attempt within the past year.
Participants must not have prior lifetime treatment with electroconvulsive therapy, ketamine/esketamine, deep brain stimulation, or transcranial magnetic stimulation.
Participants must not have recent history of alcohol/substance abuse or use of cannabis.
Trial design
Treatments tested in this trial
- BMS-986511
- Placebo
Treatment groups
200 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov